Helen Angell
Helen Angell is a Director in the Oncology, Translational Science team in Cambridge, UK
Helen received her Ph.D. ‘Immune Modulation of the Tumour Microenvironment’ from the University of Nottingham School of Pharmacy, funded by AstraZeneca and EPSRC (Engineering and Physical Sciences Research Council). Upon completing her doctorate, Helen began working in the Laboratory of Integrative Immunology at the Cordeliers Research Centre, Paris. A joint MedImmune-funded postdoc, here Helen was involved in the development and implementation of the ‘Immunoscore’. In addition, Helen undertook research into the characterisation and phenotyping of immune subpopulations, cytokines, chemokines and tumour alteration, associated with colorectal cancer progression, recurrence and metastasis.
In January 2014, Helen joined AstraZeneca’s Oncology Translational Medicine Team. Since then Helen has focussed on development of the leading Immuno-Oncology portfolio, devising strategies for segmentation of immunotherapy and small molecule combination studies with the aim to enhance patient selection for clinical trials, as well as leading external collaborations to further accelerate scientific progress in this field. Helen also led the team who developed the Tumor & Immune Cell Atlas (TICA), a core initiative generating disease linkage data to guide patient selection in clinical trials.
LATEST PROJECT
IMMUNE PROFILING STRATEGY
IMMUNO-ONCOLOGY DISEASE POSITIONING FOR NOVEL INDICATIONS
PLATFORM DEVELOPMENT FOR MEASUREMENT OF IMMUNE PARAMETERS
GROUND-BREAKING PATIENT STRATIFICATION
ARTICLE PUBLISHED
Featured publications
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2 basket study
Susan M Domchek, Sophie Postel-Vinay, Seock-Ah Im, Yeon Hee Park, Jean-Pierre Delord, Antoine Italiano, Jerome Alexandre, Benoit You, Sara Bastian, Matthew G Krebs, Ding Wang, Saiama N Waqar, Mark Lanasa, Joon Rhee, Haiyan Gao, Vidalba Rocher-Ros, Emma V Jones, Sakshi Gulati, Anna Coenen-Stass, Iwanka Kozarewa, Zhongwu Lai, Helen K. Angell, Laura Opincar, Pia Herbolsheimer, Bella Kaufman. The Lancet Oncology
The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy
Daniela Bruni*, Helen K. Angell*, and Jérôme Galon. Nature Reviews Cancer
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis
The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Bernhard Mlecnik, Gabriela Bindea, Amos Kirilovsky, Helen K. Angell, Anna C. Obenauf, Marie Tosolini, Sarah Church, Pauline Maby, Tessa Fredriksen, Stéphanie Mauger, Anne Berger, Michael R. Speicher, Franck Pagès, Viia Valge-Archer, Jérôme Galon. Science Translational Medicine, 2016.
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability
Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. Bernhard Mlecnik, Gabriela Bindea, Helen K Angell, Pauline Maby, David Tougeron, Lucie Lafontaine, Mihaela Angelova, Tessa Fredriksen, Maristella Sasso, Amélie M. Bilocq, Anna C. Obenauf, Anne Berger, Patrick Bruneval, Florence Le Pessot, Arash Rafii, Michael R. Speicher, Zlatko Trajanoski, Richard Sesboüe, Thierry Frebourg, Franck Pagès, Viia Valge-Archer, Jean-Baptiste Latouche, Jérôme Galon. Immunity, 2016.
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy
Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. Pauline Maby, David Tougeron, Bernhard Mlecnik, Mohamad Hamieh, Gabriela Bindea, Helen K Angell, Tessa Fredriksen, Nicolas Elie, Emilie Fauquembergue, Jacques Benichou, Florence Le Pessot, Richard Sesboue, Thierry Frebourg, Jerome Galon, Jean-Baptiste Latouche. Cancer Research, 2015.
CXCL13-CXCR5 Signalling Is Required for the Anti-Tumour Immune Response in Colorectal Cancer
Spatio-temporal dynamics of intratumoral cells reveal the immune landscape in human cancer
Spatio-temporal dynamics of intratumoral cells reveal the immune landscape in human cancer. Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini, Amos Kirilovsky, Maximilian Waldner, Anna C. Obenauf, Helen K. Angell, Tessa Fredriksen, Lucie Lafontaine, Anne Berger, Patrick Bruneval, Wolf Herman Fridman, Christoph Becker, Franck Pagès, Michael R. Speicher, Zlatko Trajanoski, Jérôme Galon. Immunity, 2013.
The continuum of cancer immunosurveillance: Prognostic, predictive and mechanistic signatures
Microenvironnement immunitaire et survie : l’Immunoscore
Functional network tailored pipeline revealed genetic determinants of tumours associated with in situ lymphocyte proliferation and survival of cancer patients
Functional network tailored pipeline revealed genetic determinants of tumours associated with in situ lymphocyte proliferation and survival of cancer patients. Bernhard Mlecnik, Gabriela Bindea, Helen K. Angell, Maria Stella Sasso, Anna C. Obenauf, Tessa Fredriksen, Lucie Lafontaine, Amelie M. Bilocq, Amos Kirilovsky, Marie Tosolini, Anne Berger, Wolf Herman Fridman, Arash Rafii, Viia Valge-Archer, Franck Pagès, Michael R. Speicher, Jérôme Galon. Science Translational Medicine, 2014.
The immune landscape of human tumors
Towards the introduction of the Immunoscore in the classification of malignant tumors
Spatio-temporal dynamics of intratumoral cells reveal the immune landscape in human cancer
Gabriela Bindea, Bernhard Mlecnik, Marie Tosolini, Amos Kirilovsky, Maximilian Waldner, Anna C. Obenauf, Helen K. Angell, Tessa Fredriksen, Lucie Lafontaine, Anne Berger, Patrick Bruneval, Wolf Herman Fridman, Christoph Becker, Franck Pagès, Michael R. Speicher, Zlatko Trajanoski, Jérôme Galon. Immunity, 2013.
Digital pattern recognition based image analysis enables reliable quantification of immune infiltrates in distinct tissue regions of colorectal cancer and identifies a potential metastatic phenotype
Digital pattern recognition based image analysis enables reliable quantification of immune infiltrates in distinct tissue regions of colorectal cancer and identifies a potential metastatic phenotype. H.K. Angell, N. Gray, C. Womack, D.I. Pritchard, R.W. Wilkinson, M. Cumberbatch. British Journal Cancer, 2013.
The continuum of cancer immunosurveillance: Prognostic, predictive and mechanistic signatures
From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer
Cancer classification using the Immunoscore: A worldwide task force
A study into the potential role of Survivin localization in resistance to drug-induced apoptosis
TGFbeta isoform dependent Smad2/3 kinetics in human lens epithelial cells: a Cellomics analysis
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet, 2018. Franck Pagès, Bernhard Mlecnik, Florence Marliot, Gabriela Bindea, Fang-Shu Ou, Carlo Bifulco, Alessandro Lugli, Inti Zlobec, Tilman T Rau, Martin D Berger, Iris D Nagtegaal, Elisa Vink-Börger, Arndt Hartmann, Carol Geppert, Julie Kolwelter, Susanne Merkel, Robert Grützmann, Marc Van den Eynde, Anne Jouret-Mourin, Alex Kartheuser, Daniel Léonard, Christophe Remue, Julia Y Wang, P Bavi, Michael H A Roehrl, Pamela S Ohashi, Linh T Nguyen, SeongJun Han, Heather L MacGregor, Sara Hafezi-Bakhtiari, Bradly G Wouters, Giuseppe V Masucci, Emilia K Andersson, Eva Zavadova, Michal Vocka, Jan Spacek, Lubos Petruzelka, Bohuslav Konopasek, Pavel Dundr, Helena Skalova, Kristyna Nemejcova, Gerardo Botti, Fabiana Tatangelo, Paolo Delrio, Gennaro Ciliberto, Michele Maio, Luigi Laghi, Fabio Grizzi, Tessa Fredriksen, Bénédicte Buttard, Mihaela Angelova, Angela Vasaturo, Pauline Maby, Sarah E Church, Helen K Angell, Lucie Lafontaine, Daniela Bruni, Carine El Sissy, Nacilla Haicheur, Amos Kirilovsky, Anne Berger, Christine Lagorce, Je rey P Meyers, Christopher Paustian, Zipei Feng, Carmen Ballesteros-Merino, Jeroen Dijkstra, Carlijn van de Water, Shannon van Lent-van Vliet, Nikki Knijn, Ana-Maria Mușină, Dragos-Viorel Scripcariu, Boryana Popivanova, Mingli Xu, Tomonobu Fujita, Shoichi Hazama, Nobuaki Suzuki, Hiroaki Nagano, Kiyotaka Okuno, Toshihiko Torigoe, Noriyuki Sato, Tomohisa Furuhata, Ichiro Takemasa, Kyogo Itoh, Prabhu S Patel, Hemangini H Vora, Birva Shah, Jayendrakumar B Patel, Kruti N Rajvik, Shashank J Pandya, Shilin N Shukla, Yili Wang, Guanjun Zhang, Yutaka Kawakami, Francesco M Marincola, Paolo A Ascierto, Daniel J Sargent*, Bernard A Fox, Jérôme Galon
Award
Award
Award
AstraZeneca’s progress in the immuno-oncology field fills me with great excitement! Our emerging data will help us to identify and validate patient biomarkers and potential therapeutic targets, which may enable better treatment decisions, as well as potentially providing novel opportunities with our advancing DNA Damage Response portfolio.
Our people share a common purpose: to push the boundaries of science to deliver life-changing medicines.
Stories from our people and our partners reveal the passion, energy and knowledge that enable us to put science at the heart of everything we do.
We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
Join AstraZeneca
and help us deliver life-changing medicines
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.